Global Management Structure

The Astellas Group has established a management structure as described below.

Top Management (as of October 2022)

In order to build an optimal management system capable of agile and appropriate decision-making, Astellas maintains a global organizational structure covering the entire Group across nearly all of its divisions including those of Research, Development, Pharmaceutical Technology, and administrative functions, and appoints Top Management to take charge of such activities. Top management consists of the Representative Director, President and CEO and members who are in charge of each business area.
 

Kenji Yasukawa, Ph.D.

Kenji Yasukawa, Ph.D.
Representative Director,
President and Chief Executive Officer (CEO)

Division in charge: External Relations, Healthcare Policy, Internal Audit, Sustainability

Naoki Okamura

Naoki Okamura
Representative Director, Executive Vice President,
Chief Strategy Officer (CStO)

Division in charge: Advanced Informatics and Analytics, Business Development, Corporate Strategy, Information Systems, iota Biosciences, Patient Centricity, Primary Focus Lead Blindness & Beyond, Primary Focus Lead Genetic Regulation, Primary Focus Lead Immune Homeostasis, Primary Focus Lead Immuno-Oncology, Primary Focus Lead Mitochondria, Rx+ Business Accelerator, Transformation Office

Yukio Matsui

Yukio Matsui
Chief Commercial Officer (CCO)

Division in charge: Established Markets Commercial, Gene Therapy Commercial, Greater China Commercial, International Markets Commercial, Japan Commercial, United States Commercial, Commercial Capabilities, Commercial Strategy, Market Access & Pricing, Strategic Brand Marketing Medical Specialties, Strategic Brand Marketing Oncology

Yoshitsugu Shitaka, Ph.D.ツ

Yoshitsugu Shitaka, Ph.D. 
Chief Scientific Officer (CScO)

Division in charge: Affiliate Engagement, Applied Research & Operations, Discovery Accelerator, Gene Therapy Research & Technical Operations, Immuno-Oncology, Institute for Regenerative Medicine, Mitobridge, Research Strategy & Communications, Targeted Protein Degradation, Universal Cells, Xyphos Biosciences

Minoru Kikuoka

Minoru Kikuoka
Chief Financial Officer (CFO)

Division in charge: CFO Office, Corporate Advocacy & Relations, Corporate Finance & Control, Global Business Services, Procurement, Treasury & Tax

Catherine Levitt

Catherine Levitt
General Counsel (GC)

Division in charge: Legal

Hideki Shima

Hideki Shima
Chief Manufacturing Officer (CMfgO)

Division in charge: Pharmaceutical Technology

Tadaaki Taniguchi, M.D., Ph.D.

Tadaaki Taniguchi, M.D., Ph.D.
Chief Medical Officer (CMO)

Division in charge: Development, Medical Affairs, M&D Strategy & Operations, Pharmacovigilance, Quality Assurance, Regulatory Affairs

Katsuyoshi Sugita

Katsuyoshi Sugita
Chief People Officer and Chief Ethics & Compliance Officer (CPO & CECO)

Division in charge: Corporate Risk Management, Ethics & Compliance, Executive Office, Human Resources

 

Executive Committee (as of October 2022)

Astellas has the Executive Committee, chaired by the Representative Director, President and CEO, as a body for discussion on important matters in global management of the Astellas Group. Standing members consist of Top Management. Extended members include the division heads responsible for development and pharmaceutical technology functions together with the division heads responsible for each commercial region, and these members participate in any necessary discussions at the request of the chairman.

Standing Members

Representative Director, 
President and Chief Executive Officer (CEO)
Kenji Yasukawa, Ph.D.
Representative Director, 
Executive Vice President, Chief Strategy Officer (CStO)
Naoki Okamura
Chief Commercial Officer (CCO) Yukio Matsui
Chief Scientific Officer (CScO) Yoshitsugu Shitaka, Ph.D.
Chief Financial Officer (CFO) Minoru Kikuoka
General Counsel (GC) Catherine Levitt
Chief Manufacturing Officer (CMfgO) Hideki Shima
Chief Medical Officer (CMO) Tadaaki Taniguchi, M.D., Ph.D.
Chief People Officer and Chief Ethics & Compliance Officer (CPO & CECO) Katsuyoshi Sugita


Extended Members

President, Pharmaceutical Technology Hideki Shima*
President, Development Andrew Krivoshik, M.D., Ph.D.
President, Established Markets Commercial Claus Zieler
President, Greater China Commercial Hiroshi Hamaguchi
President, International Markets Commercial Leon Moore
President, Japan Commercial Yasuhiro Tsutsui
President, United States Commercial Mark Reisenauer

*Hideki Shima, Chief Manufacturing Officer, concurrently holds the position of President, Pharmaceutical Technology.